Table 2.
COPD medications in the year after COPD diagnosis in patients categorised by baseline LRTI frequency and severity
| Overall N=2 15 234 |
None n=1 58 074 | 1 mild n=18 081 | ≥2 mild n=6133 | 1 moderate n=19 787 | ≥2 moderate n=6227 | ≥1 severe 6932 |
|
| Any COPD medications | 148 655 (69.1) | 106 778 (67.6) | 12 583 (69.6) | 4467 (72.8) | 15 403 (77.8) | 5109 (82.1) | 2617 (37.8) |
| Maintenance inhaled therapies | |||||||
| Any COPD maintenance medications | 125 540 (58.3) | 89 637 (56.7) | 10 690 (59.1) | 3832 (62.5) | 13 022 (65.8) | 4485 (72.0) | 3874 (55.9) |
| No COPD maintenance medications | 89 694 (41.7) | 68 437 (43.3) | 7391 (40.9) | 2301 (37.5) | 6765 (34.2) | 1742 (28.0) | 3058 (44.1) |
| LABA monotherapy | 4096 (1.9) | 3062 (1.9) | 285 (1.6) | 93 (1.5) | 446 (2.3) | 146 (2.3) | 64 (0.9) |
| LAMA monotherapy | 20 328 (9.4) | 14 896 (9.4) | 1912 (10.6) | 604 (9.9) | 1802 (9.1) | 497 (8.0) | 617 (8.9) |
| ICS monotherapy | 14 243 (6.6) | 10 783 (6.8) | 943 (5.2) | 264 (4.3) | 1563 (7.9) | 491 (7.9) | 199 (2.9) |
| LABA/ICS dual therapy | 38 284 (17.8) | 27 590 (17.5) | 1073 (5.9) | 1055 (17.2) | 4214 (21.3) | 1549 (24.9) | 947 (13.7) |
| LABA/LAMA dual therapy | 8837 (4.1) | 6476 (4.1) | 1073 (5.9) | 388 (6.3) | 438 (2.2) | 104 (1.7) | 358 (5.2) |
| LAMA/ICS dual therapy | 3137 (1.5) | 2234 (1.4) | 242 (1.3) | 89 (1.5) | 360 (1.8) | 131 (2.1) | 81 (1.2) |
| Triple therapy | 36 615 (17.0) | 24 596 (15.6) | 3306 (18.3) | 1339 (21.8) | 4199 (21.2) | 1567 (25.2) | 1608 (23.2) |
| Short-acting therapies | |||||||
| SABA | 114 354 (90.1) | 81 630 (90.2) | 10 029 (93.1) | 3606 (93.3) | 11 806 (87.5) | 3942 (86.4) | 3341 (91.6) |
| SAMA | 2448 (1.9) | 1770 (2.0) | 157 (1.5) | 55 (1.4) | 320 (2.4) | 107 (2.3) | 39 (1.1) |
| SAMA/SABA | 10 060 (7.9) | 7122 (7.9) | 583 (5.4) | 206 (5.3) | 1368 (10.1) | 514 (11.3) | 267 (7.3) |
Any COPD medications includes any maintenance COPD medications or any short-acting therapies. COPD maintenance therapies include any combination of LABA, LAMA, ICS. Triple therapy=LABA/LAMA/ICS. Short-acting therapies include SABA, SAMA. Numbers are n(%).
COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; LRTI, lower respiratory tract infection; SABA, short-acting beta agonists; SAMA, short-acting muscarinic antagonists.